Targets to Therapies: Mitochondrial Target Validation
Funds research to validate mitochondrial targets for Parkinson’s disease by clarifying mechanisms, biomarkers, and tools to advance therapeutic development.
Funder: Michael J. Fox Foundation for Parkinson's Research
Due Dates: No fixed deadline (rolling submissions)
Funding Amounts: Typical award size and duration vary by project; budgets must be well-justified and milestone-driven.
Summary: Supports research to validate mitochondrial targets relevant to Parkinson’s disease, focusing on mechanisms, biomarkers, and enabling tools to advance therapeutic development.
Key Information: Open Science Policy applies—data, code, and outputs must be shared openly and promptly.
Description
This program funds research to build a robust evidence base for mitochondrial targets that are highly relevant to Parkinson’s disease. The goal is to clarify the human relevance of these targets, define their mechanisms in Parkinson's-relevant contexts, establish target engagement, and develop enabling tools and assays. Supported activities include target modulation in cell and animal models, linking target biology to patient samples, clarifying mechanisms of action, identifying and validating biomarkers, and characterizing biological safety in animal models. The program prioritizes projects that address known gaps such as human modulation and biomarker linkage, and that generate reproducible, translatable data to inform therapeutic decision-making.
